Critical points for sepsis management at the patient bedside

Minerva Anestesiologica

Volumn 69, Issue 1-2, 2003, Pages 35-65

  Tulli, G ^a,b  

^a SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^b Ospedale Nuovo S Giovanni di Dio   (Italy)

Author keywords

Blood coagulation; Calcitonin; Inflammation; Multiple organ failure; Protein C; Sepsis; Shock, septic

Indexed keywords

ACTIVATED PROTEIN C; CORTICOSTEROID; DROTRECOGIN; OXYGEN;

ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; BLEEDING; BLOOD CLOTTING; DEATH; DISEASE COURSE; DISEASE SEVERITY; HEMODYNAMICS; HUMAN; INFLAMMATION; MEDICAL LITERATURE; MORTALITY; MULTIPLE ORGAN FAILURE; PHILOSOPHY; REVIEW; SEPSIS; SEPTIC SHOCK; SURGICAL TECHNIQUE; HOSPITAL INFORMATION SYSTEM; IMMUNOLOGY; MONITORING; PATHOLOGY; PHYSIOLOGY;

BLOOD COAGULATION; HUMANS; INFLAMMATION; MONITORING, PHYSIOLOGIC; POINT-OF-CARE SYSTEMS; SEPSIS;

EID: 0038262890     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Bone RC. Sir Isaac Newton, sepsis, SIRS and CARS. Crit Care Med 1996;24:1125-8.
2. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definition of sepsis and organ failure and guidelines for the use of innovative therapy in sepsis. Chest 1992;20:864-74.
3. Kawakami K, Kodate J, Iida K, Shirai R, Abe K, Khono S. Reduced immune function and malnutrition in the elderly. Thoeku J Exp Med 1999;187:157-71.
4. Tang E, Tang G, Berne TV. Prognostic indicators in fungemia of the surgical patient. Arch Surg 1993;128:759-62.
5. Best GK, Scott DF, Kling M, Crowll WF, Kirkland JJ. Enhanced susceptibility of male rabbits to infection with a toxic shock strain of staphylococcus aureus. Infect Immun 1984;46:727-32.
6. Zelweger R, Wichmann MW, Ayala A, Stein S, De Maso CM, Chaudry IH. Females in proestrus state maintain slenic immune functions and tolerate sepsis better than males. Crit Care Med 1997;25:106-10.
7. Oherholzer A, Kerel M, Zellweger R, Steckholzer U, Trentz O, Ertel W. Incidence of septic complications and multiple organ failure in severely injured patients is sex specific. J Trauma 2000;48:932-7.
8. Wichmann MV, Inhorn D, Schildberg FW. Incidence and mortality of severe sepsis in surgical intensive care. Influence of gender on disease process and outcome. Shock 1998;10 Suppl:3.
9. Schroder J, Kahlke V, Staubach KH, Zabel P, Stuber F. Gender differences in human sepsis. Arch Surg 1998;133:1200-5.
10. Pittet D, Thienent B, Wenzel RP, Li N, Gurman G. Importance of pre-existing comorbidities for prognosis of septicemia in critically ill patients. Intensive Care Med 1993;19:265-72.
11. Chandra RK. Nutrition, immunity and infection. Proc Natl Acad Sci U S A 1996;93:14304-7.
12. Leibovici L, Saura Z, Konisberger H, Kalter-Leibovici O, Pitlik SD, Ducker M. Bacteremia in adult diabetic patients. Diabetes Care 1991;14:89-94.
13. Rubio Felix S, Aznar Munoz R, Martin Algera I, Egidio Murdano M, Ferrero Cancer M, Mairol Clover P et al. Bacteremia in the elderly: associated and prognostic factors. Rev Clin Esp 1998;198:7-10.
14. Faist E, Kupper T, Baker CC, Chaudry IH, Dwyer J, Baue AE. Depression of cellular immunity after major injury; its association with post-traumatic complications and its reversal with immunomodulation. Arch Surg 1986;121:1000-5.
15. Staphan RNKTS, Qeha AS, Baue AE, Chaudry IH. Hemorrhage without tissue trauma produces immunosuppression and enhances susceptibility to sepsis. Arch Surg 1987;122:62-8.
16. Taber MG, Shibl AM, Hackbarth CJ, Larrcik JW, Sande MA. Antibiotic therapy, endotoxin concentration in cerespinal fluid and brain edema in experimental escherichia coli meningitis in rabbits. J Infect Dis 1987;156:456-62.
17. Orman KL, English BK. Effects of antibiotic class on the macrophage inflammatory response to streptococcus pneumonia. J Infect Dis 2000;182:1561-5.
18. Van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF. Epinephrine inhibits TNF α and potentiates IL-10 production during human endotoxemia. J Clin Invest 1996;97:713-9.
19. Bergman M, Gornikiewicz A, Sautner T, Wladmann E, Welzer T, Mittlbock M et al. Attenuation of catecholamine induced immunosuppression in whole blood from patients with sepsis. Shock 1999;12:421-7.
20. Burns AM, Keogan M, Donaldson M, Brown DL, Park GR. Effects of inotropes on human leukocyte numbers, neutrophil function and lymphocyte subtypes. Br J Anaesth 1997;78:530-5.
21. Meduri GU, Kanangat T. Glucocorticoid treatment of sepsis and acute respiratory distress syndrome: time for a critical reappraisal. Crit Care Med 1998;26:630-3.
22. Sprung CL. Corticosteroids in septic shock: resurrection of the last rites? Crit Care Med 1998;26:627-30.
23. Spijkstra JJ, Girbes ARJ. The continuing story of corticosteroids in the treatment of septic shock. Intensive Care Med 2000;26:496-500.
24. Sauerland S, Nagelschmidt M, Mallman P, Neugebauer EAM. Risks and benefits of preoperative high doses of methylprednisolone in surgical patients: a systematic review. Drug Saf 2000;5:449-61.
25. Westendorp RGJ, Langermans JAM, Huizinga TWJ, Elouali AH, Verweij CL, Boosma DI et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997;349:170-3.
26. Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the TNF locus influences plasma TNF α concentrations and outcome of patients with severe sepsis. Crit Care Med 1996;24:381-4.
27. Mira JP, Cariou A, Grail F, Delclaux C, Losser MR, Heshmati F et al. Association of TNF2, a TNF α promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999;282:561-8.
28. Stuber F. Genetic predisposition. In: Vincent JL, Carlet J, Opal SM, editors. Sepsis text. Boston, Dordrecht, London: Kluwer Academic Publishers; 2002.p.67-79.
29. Kumar A, Short J, Parrillo JE. Genetic factors in septic shock. JAMA 1999;282:579-81.
30. Vincent JL. Dear SIRS, I am sorry to say I do not like you... Grit Care Med 1997;25:372-4.
31. Muller B, Becker KL, Schachinger H, Rickenbacher PR, Huber PR, Zimmerli W et al. Calcitonin precursor are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000;28:977-83.
32. Al-Nawas B, Krammer I, Shah PM. Procalcitonin in diagnosis of severe infections. Eur J Med Res 1996;1:331-3.
33. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentration in patients with sepsis and infection. Lancet 1993;341:515-8.
34. Schroeder J, Staubach KHZP, Stuber F, Kremer B. Procalcitonin as a marker of severity in septic shock. Langenbecks Arch Surg 1999;384:33-8.
35. Hatherill M, Jones G, Linn E, Tibby SM, Murdoch IA. Procalcitonin aids diagnosis of adrenocortical failure. Lancet 1997;350:1749-50.
36. Reith HB, Mittelkotter U, Debus ES, Kussner C, Thiede A. Procalcitonin in early detection of postoperative complications. Dig Surg 1998;15:260-5.
37. Ugarte H, Suva E, Mercan D, De Mendonca A, Vincent JL. Procalcitonin as a marker of infection in the intensive care unit. Crit Care Med 1999;27:498-504.
38. Vincent JL. Procalcitonin: the marker of sepsis? Crit Care Med 2000;28:1226-8.
39. Opal SM. The interaction between the coagulation system and the systemic inflammatory mediators. Immune response. In: Marshall JC, Cohen J, editors. Critically ill update in intensive care and emergency medicine. Berlin, New York: Springer 2000;31:280-91.
40. Dhainaut JF, Abraham E, Opal SM. The margaux conference on critical illness: activation of the coagulation system in critical illnesses. Crit Care Med 2000;28 Suppl 9:S1-89.
41. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H et al. The SOFA (Sepsis related organ failure assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996;22:707-10.
42. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score a reliable descriptor of a complex clinical outcome. Crit Care Med 1995;23:1638-52.
43. Le Gall JR, Klar J, Lemeshow S, Saulnier F, Alberti C, Artigas A et al. The Logistic organ dysfunction in the intensive care unit. JAMA 1996;276:802-10.
44. Bernard G, Artigas A, Brigham R, Carlet J, Falke K, Hudson L et al. The American-European consensus conference on ARDS: definitions, mechanism, relevant outcomes and clinical trials coordination. Am J Respir Crit Care Med 1994;149:818-24.
45. Artigas A, Bernard G, Carlet J, Dreyfus D, Gattinoni L, Hudson L et al. The American-European consensus conference on ARDS. Part 2: ventilatory pharmacologic supportive therapy, therapy study design, strategies and issues related to recovery and remodeling. Am J Respir Crit Care Med 1998;157:1332-47.
46. Brower RG, Matthay M, Morris A, Schoufold D, Thompson BT, Wheeler A, for the ARDS Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for ALI and ARDS. N Engl J Med 2000;342:1301-8.
47. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Crit Care Med 1999;27:639-60.
48. Vincent JL. Hemodynamic support in septic shock. Intensive Care Med 2001;27:S80-92.
49. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B et al. for the Early Goal directed Therapy Collaborative Group. Early goal directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
50. Evans TW. Hemodynamic and metabolic therapy in critically ill patients. N Engl J Med 2001;345:1417-8.
51. Annane D. Steroids for septic shock : the French randomized trial. Shock 2000;13 Suppl:160-1.
52. Annane D, Sebille V, Trache G, Raphael JC, Gayda P, Bellisant E. A 3 level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000;2834:1038-45.
53. Martin C, Leone M, Ayern ML. How to use norepinephrine in septic shock patients. Intensivemed 2000;37:507-13.
54. Cordingly J, Palazzo M. Renal rescue management of impending renal failure. In: Vincent JL, editor. Yearbook of intensive care and emergency medicine. Berlin: Springer; 1996.p.675-89.
55. Short A, Cumming A. ABC of intensive care renal support. Br Med J 1999;319:41-3.
56. Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle III WA. Hemodynamic and metabolic effects of low dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001;29:487-93.
57. Mathur VS, Swan SK, Lambrecht LJ, Anjum S, Fellmann J, McGuire D et al. The effects of fenoldopam: a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999;27:1832-7.
58. Ronco C, Bellomo R, Howel P, Brendolan A, Dan M, Piccini P et al. Effects of different doses in continuous venovenous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000;355:26-30.
59. Ten Gate H. Pathophysiology of disseminated intravascular coagulation in sepsis. Crit Care Med 2000:28: S9-11.
60. Fisher CJ, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P et al. Influence of an anti tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993:21:318-27.
61. Bone RC. Why sepsis trials fail. JAMA 1996;276:565-7.
62. Cohen J, Carlet J Intersept study group. Intersept an international multicenter placebo controlled trial on monoclonal antibody to human tumor necrosis factor α in patients with sepsis. Crit Care Med 1996;24:1431-40.
63. Pinsky MR, Vincent JL, Deviere J, Alegre M, Khan RJ, Dupont E. Serum cytokine levels in human septic shock: relation to multiple system organ failure and mortality. Chest 1993:103:565-75.
64. Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from randomised double blind, placebo controlled trial Phase III rhlL-1ra Sepsis Syndrome Study Group. JAMA 1994;23:1836-43.
65. Fisher CJ, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G et al. Initial evaluation of human recombinant interleukin 1 receptor antagonist in the treatment of sepsis syndrome: a randomised, open label, placebo controlled multicenter trial. Crit Care Med 1994;22:12-21.
66. Opal SM, Fisher CJ, Dhainaut JFA, Vincent JL, Brase R, Lowry SF et al. Interleukin Receptor Antagonist Sepsis Investigator Group, Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomised double blind, placebo controlled, multicenter trial. Crit Care Med 1997;25:115-24.
67. Lyons A, Kelly JL, Rodrcik ML, Mannick JA, Lederer JA. Major injury induces increased production of interleukin 10 by cells of the immune system with a negative impact on resistance to infection. Ann Surg 1997;226:450-60.
68. Chandra RK. Numerical and functional deficiency in T helper cells in protein energy malnutrition. Clin Exp Immunol 1983;51:123-32.
69. Chandra RK. Nutrition, immunity and infection. Proc Natl Acad Sci U S A 1996;93:14304-7.
70. Brune IB, Wilke W, Hensler T, Holzmann B, Siewert JR. Down regulation of T helper type 1 immune response and altered proinflammatory and anti-inflammatory T cell cytokine balance following conventional but not laparoscopic surgery. Am J Surg 1999;177:55-60.
71. Ferguson NR, Galley HF, Webster NR. T helper cell subset ratios in patients with severe sepsis. Intensive Care Med 1999;25:106-9.
72. Meakins W, Pietsch JB, Christou NV, Maclean LD. Predicting surgical infection before the operation. World J Surg 1980;4:439-50.
73. Andoh A, Fujiyama Y, Kitoh K, Hodohara K, Bamba T, Hosoda S. Flow cytometric assay for phagocytosis of human monocytes mediated via Fc γ receptors and complement receptor CR1 (CD35). Cytometry 1991;12:677-86.
74. Hubel K, Hegener K, Schnell R, Mansmann G, Oberhauser F, Staib P et al. Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. Ann Hematol 1999;78:37-77.
75. 125J labeled polyvinyl pyrrolidone. Clin Exp Immunol 1975;20:489-96.
76. Low A, Hotze A, Krapf F, Schranz W, Manger BJ, Mahlstedt J et al. The nonspecific clearance function of the reticuloendothelial system in patients with immune complex mediated diseases before and after therapeutic plasmapheresis. Rheumatol Int 1985;5:69-72.
77. Morgan AG, Steward MW. Macrophage clearance function and immune complex disease in New Zealand Black/White F1 hybrid mice. Clin Exp Immunol 1976;26:133-6.
78. Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC, Thomas M. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J Immunol 1983;130:1910-7.
79. Jochum M. Hamostasefactoren, zytokine, leukozytare proteasen und losliche adhasionsmolekule bei sepsis und systemic inflammatory response syndrome (SIRS). VII Rostocker symposium. Klin probleme Weller. Heidelberg, Berlin: Springer Verlag; 1998.p.1-58.
80. Brunkhorst FM, Reinhart K. Diagnostic approach to sepsis-state of the art. In: Baue AE, Berlot G, Gullo A, Vincent JL, editors. Sepsis and organ dysfunction: from chaos to rationale. Milano: Springer-Verlag Italia; 2002. p.151-67.
81. Wakefield CH, Carey PD, Foulds S, Monson JRT, Guillou PJ. Changes in major histocompatibility complex class II expression immunocytes and T cells of patient developing infection after surgery. Br J Surg 1993;80:205-9.
82. Wakefield CH, Barclay GR, Fearon KCH, Goldie AS, Ross JA, Grant IS et al. Proinflammatory mediator activity, endogenous antagonists and the systemic inflammatory response in intra abdominal sepsis. Br J Surg 1998;85:18-25.
83. Cheadle WG, Hershman MJ, Wellhausen SR, Polk HC. HLA-DR antigen expression on peripheral blood immunocytes correlates with surgical infection. Am J Surg 1991;161:639-46.
84. Carlei F, Schietroma M, Cianca G, Risetti A, Mattucci S, Ngome Enang G, Simi M et al. Effects of laparoscopic and conventional open cholecystectomy on human leukocyted antigen DR expression on peripheral blood monocytes: correlations with immunologic status. World J Surg 1999:23:18-22.
85. Doecke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P et al. Monocyte deactivation in septic patients: restoration by IFN γ treatment. Nat Med; 1997.p.678-81.
86. Deitch EA. Cytokines yes, cytokines no, cytokines maybe? Grit Care Med 1993;21:817-9.
87. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I et al. High dose antithrombin III in severe sepsis: randomised controlled trial. JAMA 2001;286:1869-78.
88. Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin and heparan sulfate. Crit Care Med 2002;30 Suppl:S325-31.
89. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez Rodriguez A et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
90. Cavaillon JM, Adib-Conquy M. Involvement of pro and anti inflammatory cytokines in sepsis. In: Vincent JL, Carlet J, Opal SM, editors. The sepsis text. Boston, Dordrecht, London: Kluwer Academic Publishers; 2002. p.159-95.
91. Hack CE. The coagulation system in sepsis. In: Vincent JL, Carlet J, Opal SM, editors. The sepsis text. Boston,. Dordrecht, London: Kluwer Academic Publishers; 2002. p.687-704.
92. Faust SN, Levin M, Harrison OB. Dysfunction ofendothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345:408-16.
93. Levi M, ten Gate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586-92.
94. Thijs LG. Coagulation abnormalities in critical illness. In:Evans TW, Fink MP, editors. Mechanisms of organ dysfunction in critical illness. Heidelberg: Springer Verlag; 2000.p.376-93.
95. Tulli G, Zolfanelli F. Pathology in ICU. Tuscany Critical Care Group III Annual Meeting Critical Care Insights Florence June 14th-17th, 2000 Proceedings Book. Florence: Tuscany Critical Care Editorial Group; 2000.p. 15-31.